Claims for Patent: 7,795,312

Summary for Patent: 7,795,312

Title:	Method for treating abdominal discomfort
Abstract:	A method for treating irritable bowel syndrome in a mammalian subject includes administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E.sub.1 or 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E.sub.1, or a salt, ether, ester or amide thereof, to the subject. A method for treating abdominal discomfort associated with irritable bowel syndrome in a mammalian subject includes administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E.sub.1 or 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E.sub.1, or a salt, ether, ester or amide thereof, to the subject.
Inventor(s):	Ueno; Ryuji (Montgomery, MD), Kuno; Sachiko (Montgomery, MD)
Assignee:	Sucampo AG (Zug, CH)
Application Number:	10/745,689
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,795,312
Patent Claims:	1. A method for treating irritable bowel syndrome in a mammalian subject, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E.sub.1, or a salt, ether, ester or amide thereof, to the subject. 2. The method as described in claim 1, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E.sub.1, or a pharmaceutically acceptable salt, ester or amide thereof. 3. The method as described in claim 1, which comprises systemic administration 1-4 times per day or continuous administration in the amount of 0.01-100 .mu.g/kg per day or a 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E.sub.1 compound. 4. A method for treating as described in claim 2, wherein the administration is in the amount of 0.1-10 .mu.g/kg per day. 5. The method as described in claim 1, which comprises systemic administration 1-4 times per day or continuous administration at the amount of 0.01-100 .mu. g/kg per day. 6. The method as described in claim 5, wherein the administration is at the amount of 0.1-10 .mu.g/kg per day. 7. A method for treating irritable bowel syndrome in a mammalian subject, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro prostaglandin E.sub.1 or a salt, ether, ester or amide thereof, to the subject. 8. The method as described in claim 7, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E.sub.1, or a pharmaceutically acceptable salt, ester or amide thereof. 9. The method for treating irritable bowel syndrome in a as described in claim 8, which comprises systemic administration 1-4 times per day or continuous administration in the amount of 0.01-100 .mu.g/kg per day. 10. The method as described in claim 8, wherein the administration is in the amount of 0.1-10 .mu.g/kg per day. 11. The method as described in claim 7, which comprises systemic administration 1-4 times per day or continuous administration at the amount of 0.01-100 .mu.g/kg per day. 12. The method as described in claim 7, wherein the administration is at the amount of 0.1-10 .mu.g/kg per day. 13. A method for treating abdominal discomfort associated with irritable bowel syndrome in a mammalian subject, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E.sub.1, or a salt, ether, ester or amide thereof, to the subject. 14. The method as described in claim 13, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E.sub.1, or a pharmaceutically acceptable salt, ester or amide thereof. 15. The method as described in claim 14, which comprises systemic administration 1-4 times per day or continuous administration in the amount of 0.01-100 .mu.g/kg per day. 16. The method as described in claim 13, which comprises systemic administration 1-4 times per day or continuous administration in the amount of 0.01-100 .mu.g/kg per day. 17. The method as described in claim 13, wherein the administration is in the amount of 0.1-10 .mu.g/kg per day. 18. A method for treating abdominal discomfort associated with irritable bowel syndrome in a mammalian subject, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro prostaglandin E.sub.1, or a salt, ether, ester or amide thereof, to the subject. 19. The method as described in claim 18, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E.sub.1, or a pharmaceutically acceptable salt, ester or amide thereof. 20. The method as described in claim 19, which comprises systemic administration 1-4 times per day or continuous administration in the amount of 0.01-100 .mu.g/kg per day. 21. The method as described in claim 18, which comprises systemic administration 1-4 times per day or continuous administration in the amount of 0.01-100 .mu.g/kg per day. 22. The method as described in claim 18, wherein the administration is in the amount of 0.1-10 .mu.g/kg per day.